These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19019404)

  • 21. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
    Figueiredo A; Moore KL; Mak J; Sluis-Cremer N; de Bethune MP; Tachedjian G
    PLoS Pathog; 2006 Nov; 2(11):e119. PubMed ID: 17096588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.
    Huang W; Gamarnik A; Limoli K; Petropoulos CJ; Whitcomb JM
    J Virol; 2003 Jan; 77(2):1512-23. PubMed ID: 12502865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteolytic cleavage at the Gag-Pol junction in avian leukosis virus: differences in vitro and in vivo.
    Stewart L; Vogt VM
    Virology; 1994 Oct; 204(1):45-59. PubMed ID: 7522375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication.
    Morin N; Cherry E; Li X; Wainberg MA
    J Hum Virol; 1998; 1(3):240-7. PubMed ID: 10195247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.
    Popov S; Strack B; Sanchez-Merino V; Popova E; Rosin H; Göttlinger HG
    J Virol; 2011 Apr; 85(8):3792-801. PubMed ID: 21289110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
    Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
    J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of reverse transcriptase sequences in Pol with Gag and LysRS in the HIV-1 tRNALys3 packaging/annealing complex.
    Saadatmand J; Guo F; Cen S; Niu M; Kleiman L
    Virology; 2008 Oct; 380(1):109-17. PubMed ID: 18708237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization.
    Depollier J; Hourdou ML; Aldrian-Herrada G; Rothwell P; Restle T; Divita G
    Biochemistry; 2005 Feb; 44(6):1909-18. PubMed ID: 15697216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.
    Olivares I; Mulky A; Boross PI; Tözsér J; Kappes JC; López-Galíndez C; Menéndez-Arias L
    J Mol Biol; 2007 Sep; 372(2):369-81. PubMed ID: 17651754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients.
    Dunn LL; Boyer PL; Jane McWilliams M; Smith SJ; Hughes SH
    Virology; 2015 Oct; 484():127-135. PubMed ID: 26093496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutant.
    Huang M; Zensen R; Cho M; Martin MA
    J Virol; 1998 Mar; 72(3):2047-54. PubMed ID: 9499059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
    Gatanaga H; Hachiya A; Kimura S; Oka S
    Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.
    Sluis-Cremer N; Arion D; Abram ME; Parniak MA
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1836-47. PubMed ID: 15183348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.